Please provide your email address to receive an email when new articles are posted on . In the PIVOTAL trial, patients undergoing hemodialysis with ferritin concentration less than 400 µg/L and a ...

Use of erythropoiesis-stimulating agents decreased, while use of iron increased. Meta-analysis reveals no statistically significant increase in the risks of infection, cardiovascular events, ...

Patients on hemodialysis who received high-dose had similar rates of infection and rates of hospitalization for infection compared with those treated with low-dose IV iron, a secondary analysis of the ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — The PIVOTAL Trial has shown in patients undergoing hemodialysis, that the use of higher-dose IV iron ...

Until now, no other treatment has been shown to reduce heart attack risk in patients on dialysis. High-dose intravenous (IV) iron reduces the risk for acute myocardial infarction in patients receiving ...

A little over 3 years ago, researchers reported findings from PIVOTAL, the largest prospective, randomized trial to assess an aggressive versus conservative iron-repletion strategy in patients with ...

First and only high-dose intravenous iron for iron deficiency anemia of various etiologies SHIRLEY, N.Y.--(BUSINESS WIRE)--American Regent, Inc., a subsidiary of Luitpold Pharmaceuticals, Inc. (a ...

A new paper in Cardiovascular Research, published by Oxford University Press, indicates that iron treatments may reduce heart attacks in patients experiencing kidney failure undergoing dialysis.

A single dose of intravenous (IV) iron dextran is the most cost-effective treatment for women with heavy menstrual bleeding ...

SAN DIEGO — The proactive use of high-dose intravenous (IV) iron can reduce the amount of erythropoiesis-stimulating agent needed to treat anemia in dialysis patients with no short-term increase in ...